References
Carswell CI, Plosker GL. Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs 2002; 62(5): 841–70
Weitz JI, Hirsh J. New anticoagulant drugs. Chest 2001; 119 Suppl.: 95S–107S
Bates SM, Weitz JI. Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin. Cardiovasc Res 1999; 41(2): 418–32
Bittl JA, Strony J, Blinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995 Sep 21; 333(12): 764–9
Bittl JA, Feit F. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. Am J Cardiol 1998 Oct 22; 82(8B): 43P–49P
Bittl JA, Ahmed WH. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Am J Cardiol 1998 Oct 22; 82(8B): 50P–6P
Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable of postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001 Dec; 142: 952–9
Antman EM, Braunwald E. A second look at bivalirudin [letter]. Am Heart J 2001; 142(6): 929–31
Strony J, Rusterholtz L, Maraganore J, et al. Bivalirudin (Hirulog) reduces ischaemic rebound in comparison to heparin after coronary angioplasty [abstract]. Eur Heart J 1998 Aug; 19 (Abstr. Suppl.): 46
Campbell KR, Wildermann N, Janning C, et al. Bivalirudin during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia: interim results of the ATBAT Trial [abstract]. Am J Cardiol 2000 Oct 16; 86: 73–4
Burchenal JE, Marks DS, Tift Mann J, et al. Effect of direct thrombin inhibition with bivalirudin (Hirulog) on restenosis after coronary angioplasty. Am J Cardiol 1998 Aug 15; 82(4): 511–5
White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving Streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 1997 Oct 7; 96(7): 2155–61
Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001 Dec; 358: 1855–63
Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999 Nov 16: 100(20): 2049–53
Rights and permissions
About this article
Cite this article
Biyalirudin: a proven alternative to heparin for PTCA in patients with unstable angina. Drugs Ther. Perspect 18, 1–4 (2002). https://doi.org/10.2165/00042310-200218120-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200218120-00001